The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study.

The life expectancy of patients with psychotic disorders is significantly shorter than that of the general population; antipsychotic-induced metabolic disorders play a significant role in reducing life expectancy. Both metabolic syndrome (MetS) and schizophrenia are multifactorial conditions. One area where the two conditions overlap is oxidative stress, which is present in both diseases.

[NOS1AP Gene Polymorphism and Body Fat in Patients with Schizophrenia: A Search for Associations].

Long-term pharmacotherapy in patients with schizophrenia can provoke antipsychotic-induced obesity. This side effect does not always meet the criteria for metabolic syndrome (MS), primarily central obesity. However, this significantly reduces the quality of life of patients and is a risk factor for the development of many diseases.

gene polymorphisms and BDNF serum concentration in schizophrenia patients: a pilot study.

Objectives: The search for the genetic basis of the leading symptom domains of schizophrenia is of interest. BDNF is a universal neurotrophin that promotes brain development and neuroplasticity. Our aim was to study polymorphisms of the gene and serum levels of BDNF in schizophrenia and to analyze the concentration of this marker depending on clinical and genetic characteristics.